All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
CAT | Product Name | Target Species | TCR Clone | Host Species | Epitope | Allele | Vector Type | Inquiry & Datasheet |
TCR-YC1271 | Human anti-UL28 T cell receptor (FRC1-1), pCDTCR1 | HCMV | FRC1-1 | Human | FRCPRRFCF | HLA-Cw*0702 | Lentiviral vector | |
TCR-YC1272 | Human anti-UL28 T cell receptor (FRC1-2), pCDTCR1 | HCMV | FRC1-2 | Human | FRCPRRFCF | HLA-Cw*07:02 | Lentiviral vector | |
TCR-YC1273 | Human anti-UL28 T cell receptor (FRC1-3), pCDTCR1 | HCMV | FRC1-3 | Human | FRCPRRFCF | HLA-Cw*07:02 | Lentiviral vector | |
TCR-YC1274 | Human anti-UL28 T cell receptor (FRC1-4), pCDTCR1 | HCMV | FRC1-4 | Human | FRCPRRFCF | HLA-Cw*07:02 | Lentiviral vector | |
TCR-YC1275 | Human anti-UL28 T cell receptor (FRC1-5), pCDTCR1 | HCMV | FRC1-5 | Human | FRCPRRFCF | HLA-Cw*07:02 | Lentiviral vector | |
TCR-YC1276 | Human anti-UL28 T cell receptor (FRC1-6), pCDTCR1 | HCMV | FRC1-6 | Human | FRCPRRFCF | HLA-Cw*07:02 | Lentiviral vector | |
TCR-YC1277 | Human anti-UL28 T cell receptor (FRC1-7), pCDTCR1 | HCMV | FRC1-7 | Human | FRCPRRFCF | HLA-Cw*07:02 | Lentiviral vector | |
TCR-YC1278 | Human anti-UL28 T cell receptor (FRC1-8), pCDTCR1 | HCMV | FRC1-8 | Human | FRCPRRFCF | HLA-Cw*07:02 | Lentiviral vector | |
TCR-YC1279 | Human anti-UL28 T cell receptor (FRC2-1), pCDTCR1 | HCMV | FRC2-1 | Human | FRCPRRFCF | HLA-Cw*07:02 | Lentiviral vector | |
TCR-YC1280 | Human anti-UL28 T cell receptor (FRC2-2), pCDTCR1 | HCMV | FRC2-2 | Human | FRCPRRFCF | HLA-Cw*07:02 | Lentiviral vector |
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION